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Abstract
Background: Nutrilon Omneo (new formula; NF) contains high concentration of sn-2 palmitic
acid, a mixture of prebiotic oligosaccharides and partially hydrolyzed whey protein. It is
hypothesized that NF positively affects stool characteristics in constipated infants.
Methods: Thirty-eight constipated infants, aged 3–20 weeks, were included and randomized to NF
(n = 20) or a standard formula (SF; n = 18) in period 1 and crossed-over after 3 weeks to treatment
period 2. Constipation was defined by at least one of the following symptoms: 1) defecation
frequency < 3/week; 2) painful defecation; 3) abdominal or rectal palpable mass.
Results: Period 1 was completed by 35 infants. A significant increase in defecation frequency (NF:
3.5 pre versus 5.6/week post treatment; SF 3.6 pre versus 4.9/week post treatment) was found in
both groups, but was not significantly different between the two formulas (p = 0.36). Improvement
of hard stool consistency to soft stool consistency was found more often with NF than SF, but did
not reach statistical significance (90% versus 50%; RR, 1.8; 95% CI, 0.9–3.5; p = 0.14). No difference
was found in painful defecation or the presence of an abdominal or rectal mass between the two
groups. Twenty-four infants completed period 2. Only stool consistency was significantly different
between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft
stools on SF and hard stools on NF, McNemar test p = 0.046).
Conclusion: The addition of a high concentration sn-2 palmitic acid, prebiotic oligosaccharides and
partially hydrolyzed whey protein resulted in a strong tendency of softer stools in constipated
infants, but not in a difference in defecation frequency. Formula transition to NF may be considered
as treatment in constipated infants with hard stools.
Background
Between 16–40% of the infants with constipation experi-
ence symptoms before the age of six months [1-3]. In
approximately 90% of infants no specific organic cause
can be found [4]. It is well established that the bowel pat-
tern in infants is influenced by the type of feeding in the
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first months after birth. Constipation is more commonly
found in formula-fed infants, who have a greater tendency
to produce hard stools compared to breast-fed infants [5].
Differences in the composition between breast- and for-
mula feeding may explain this finding.
The structure of lipids differs between human milk and
infant formulas. In both human milk and infant formulas
palmitic acid is the predominant saturated fatty acid. In
human milk 70–85% of palmitic acid is positioned at the
sn-2 position of the triacylglycerol molecule, whereas in
regular infant formulas 88–94% of palmitic acid is found
at the sn-1 and sn-3 position [6-10]. Lipolysis of triacylg-
lycerol by pancreatic lipase occurs predominantly at the
sn-1 and sn-3 positions, yielding free fatty acids and a 2-
monoacylglycerol [11,12]. Subsequently, free palmitic
acid may form insoluble calcium fatty acid soaps which
are excreted via the feces, resulting in firmer stools. Stool
hardness has been positively associated with the presence
of calcium fatty acid soaps in the stools [5]. In human
milk however, palmitic acid esterified at the sn-2 position
of the triacylglycerol molecule is well absorbed as 2-mon-
opalmitin, since it readily forms mixed micelles with bile
acids [11,13-15].
Human milk is further known to be a rich source of oli-
gosaccharides [16]. These oligosaccharides resist digestion
in the small intestine and thus reach the colon unaltered,
where they serve as prebiotics [17]. They act as growth
substrate for bifidobacteria, which are thought to have
beneficial effects on the host's health by supporting the
gut barrier, stimulating normal intestinal function, and
strengthening the immune system [18-20]. In addition,
due to their non-digestibility, they may be considered to
be a form of soluble fibres and contribute to the softer
stools produced by breast-fed infants [17,21].
Based on these findings, the concept of adding modified
triacylglycerol and prebiotic oligosaccharides to infant
formulas has arisen. A new infant formula (NF; Nutrilon
Omneo, Nutricia Nederland BV, Zoetermeer, the Nether-
lands) was developed which contains modified vegetable
oil with a high proportion (41%) of palmitic acid at the
sn-2 position, a mixture of prebiotic oligosaccharides, par-
tially hydrolyzed whey protein and a reduced lactose con-
tent. The oligosaccharides mixture consists of 90% short-
chain galacto-oligosaccharides (GOS) and 10% long-
chain fructo-oligosaccharides (lcFOS), 0.8 g/100 ml, and
resembles human milk oligosaccharides with respect to its
molecular weight distribution and high galactose content
[22]. The effect of NF on stool frequency and consistency
has been assessed in one study in healthy term infants
[23]. Infants receiving NF were found to produce softer
stools than those fed a regular infant formula. We hypoth-
esized that this NF will also have a positive effect stool
characteristics in constipated infants.
Methods
Patients
This study was conducted in the academic medical hospi-
tal in Amsterdam and 5 non-academic hospitals in the
Netherlands. Eligible for the study were otherwise
healthy, term infants with constipation, between 3 – 20
weeks of age, who received at least 2 bottles of milk-based
formula per day. Constipation was defined as the pres-
ence of at least one of the following symptoms: 1) fre-
quency of defecation < 3/week; 2) painful defecation
(crying); 3) abdominal or rectal palpable mass [3]. Chil-
dren with Hirschsprung's disease, spinal or anal anoma-
lies, previous colonic surgery, metabolic, cerebral and
renal abnormalities were excluded. Also children who
were treated with laxatives at enrollment were excluded.
The medical ethics committees of the participated hospi-
tals approved the research protocol. All parents gave writ-
ten informed consent.
Medical history and physical examination
At enrollment, clinical history, dietary history, obstetrical
data and anthropometry were recorded. The infants were
randomized by a computer program to either NF or SF in
period 1 and crossed-over after 3 weeks to treatment
period 2. In order to mimic the taste of Nutrilon Omneo,
the whey-based control formula was partly mixed with a
formula based on hydrolyzed whey protein (mixture of
75% Nutrilon 1 and 25% Aptamil HA l). Further details
on the composition of the study formulas are given in
Table 1. Formula cans were labeled with codes to mask
identity of the study feedings. Neither the parent nor the
physicians were aware of the composition of the formula
until the entire study was completed.
During both periods parents were asked to daily record in
a diary details on formula intake, formula tolerance (vom-
iting, flatulence, colics, rash), passage of stools and stool
consistency compared to four validated photographs of
runny, mushy soft, formed soft and hard stools [21]. After
each intervention period, an out-patient clinic visit for
evaluation of data was done. During these visits, anthro-
pometric assessments and abdominal and rectal examina-
tion were performed.
Efficacy parameters
In this study it was hypothesized that the use of NF would
alleviate the symptoms of constipation. The following pri-
mary efficacy parameters were assessed: 1) defecation fre-
quency > 3/week; 2) normalization of stool consistency;
3) no more painful defecation; 4) absence of abdominal
or rectal palpable mass at physical examination. Second-Nutrition Journal 2007, 6:8 http://www.nutritionj.com/content/6/1/8
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ary outcome measures were formula tolerance and weight
gain.
Statistical analysis
Prior to the start of the study, sample size, based on a
cross-over design, was calculated to allow detection of a
30% difference in improvement between NF and SF.
Under the assumption of a significance level of 0.05 with
a power of 0.80, and 2-sided hypothesis testing, a mini-
mal sample size of 34 with 17 children in each group was
determined.
Descriptive statistical measures were calculated for base-
line characteristics. Our cross-over study was hampered by
the drop-out of a substantial number of children after they
finished period 1 and before or during the second period
of treatment (Figure 1). Only 24 children (63%) com-
pleted the cross-over study. It is highly likely that drop-out
occurred not at random, but was related to clinical out-
come (for instance early termination in period 2 because
of insufficient response). A cross-over analysis of the com-
pleters within this study could therefore lead to biased
results. Therefore we restricted our main analysis to the
first period. Essentially, this reduces our trial to a simple,
two-group parallel trial, but we rather sacrifice loss-of-
power than introducing bias. Comparisons between the
two treatment groups after period 1 were performed using
ANCOVA in case of continuous outcomes and χ2 tests for
categorical endpoints. However, we do present the results
of the patients that finished the cross-over trial to evaluate
whether the results are in the same line as the first period
results. The subgroup analysis was performed using either
a paired sample t  test or the McNemar test for paired
observations. Differences were considered statistically sig-
nificant when the P-value was less than 0.05.
Results
Patient characteristics
Between April 2002 and January 2004, 41 constipated
infants were enrolled in the study. Directly after inclusion
3 infants dropped out for unknown reasons, because par-
ents did not show up at the next outpatient clinic visit.
Thus, 38 patients were randomized and received either SF
(n = 18) or NF (n = 20). Figure 1 shows a scheme of the
trial profile. A total of 35 infants completed the first
period of 3 weeks. Only 24 patients completed the full
cross-over study. The various reasons for withdrawal of
the study are described in the legends of Figure 1. Data
analysis was based on the group of 35 patients that com-
pleted period 1 and a subgroup analysis of 24 patients
who completed the cross-over.
The median age at enrollment of the 38 infants (19 male)
was 1.7 months, whereas the median age at onset of con-
stipation was 2 weeks. The mean defecation frequency
was 3,5/week and 45% of all infants had a defecation fre-
Table 1: Composition of the study formulas
Nutrients per 100 ml SF * NF
Energy (kcal) 67 70
Protein (g) 1.5 1.7
Casein 0.5 -
Intact whey protein 0.6 -
Whey protein hydrolysate 0.4 1.7
Fat (triglycerides) (g) 3.5 3.3
Palmitic acid 0.6 0.6
- at the sn-2 position (%) 11.5 41.0
Linoleic acid 0.4 0.4
α-linolenic acid 0.07 0.08
Carbohydrates (g) 7.3 8.4
Lactose 7.2 2.9
Maltodextrin - 4.0
Starch - 1.5
Fibre (g) - 0.8
Oligosaccharides (90% GOS, 10% lcFOS) - 0.8
Minerals and trace elements (mg)
Calcium 53 53
Phosphorus 29 29
Sodium 22 23
Potassium 69 82
Chloride 42 44
Iron 0.5 0.5
Zinc 0.5 0.5
* mixture of 75% Nutrilon 1 and 25% Aptamil HA 1Nutrition Journal 2007, 6:8 http://www.nutritionj.com/content/6/1/8
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quency of less than 3 times per week. Furthermore, the
main symptoms of constipation were hard stool consist-
ency and painful defecation, occurring in 61% and 82% of
infants respectively. Baseline characteristics of the infants
according to randomization to SF or NF are described in
Table 2.
Clinical efficacy after period 1
Compared to baseline, a significant increase in mean def-
ecation frequency/week was found after 3 weeks from 3.5/
week to 5.3/week (difference between means, 1.8; 95%
CI: 0.81 – 2.78; p = 0.001). Mean defecation frequency/
week increased from 3.5/week pre to 5.6/week post treat-
ment with NF compared to 3.6/week pre to 4.9/week post
treatment with SF, but the increase in frequency was not
significantly different between the groups (difference
between means, 0.7; 95% CI, -0.8 – 2.3; p = 0.36,
ANCOVA) (Table 3). Improvement of hard stool consist-
ency at intake to soft stool consistency after 3 weeks inter-
vention was found more often with NF than SF, but did
not reach statistical significance (90% versus 50%; RR,
1.8; 95% CI, 0.9 – 3.5; p = 0.14). Furthermore, painful
defecation diminished in both groups; NF: 75% pre and
65% post treatment and SF: 89% pre and 67% post treat-
ment. Also a decrease in the presence of an abdominal
and/or rectal mass was found; NF: 35% pre and 10% post
treatment and SF: 44% pre and 5.6% post treatment.
However, no significant differences in both of these
Trial profile Figure 1
Trial profile * No contact after intake. ** In period 1 three SF patients dropped out; 2 patients stopped because of severe 
constipation; one patient switched to hypoallergenic feeding, because of suspected cow's milk protein allergy. *** Parents of 1 
patient decided that they did not want to cross-over because she was free of symptoms and they started openly with NF 
instead. **** Three patients dropped out after switching to NF; 2 patients stopped after less than 1 week because of recur-
rence of constipation symptoms. 1 patient was lost to follow-up. ***** Seven patients dropped out after switching to SF; 6 
patients stopped after one week because of recurrence of constipation symptoms. 1 patient was lost to follow-up.
Enrollment  (n=41)
Randomized (n=38)
NF (n=20) SF (n=18)
NF (n=20) SF (n=15)
drop-out: n=3**
Period 1
NF (n=15) SF (n=19)
drop-out: n=7***** drop-out: n=3****
SF (n=12) NF (n=12) Period 2
drop-out: n=3*
drop-out: n=1***Nutrition Journal 2007, 6:8 http://www.nutritionj.com/content/6/1/8
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patient characteristics were found between the two feed-
ing groups (Table 3).
Clinical efficacy after cross-over (period 1 and 2)
Only 24 infants completed the cross-over study. In these
infants, the defecation frequency was comparable for NF
and SF with a mean frequency of 5.5/week vs. 5.9/week
(Difference of means, - 0.5; 95% CI, -1,6 – 0,6; p = 0.38),
respectively. The frequency of soft stools was significantly
higher in the NF period, with 17% (n = 4) of infants hav-
ing soft stools when receiving NF but hard stools with SF,
compared to no infant with soft stools when receiving SF
and hard stools with NF (McNemar test, p = 0.046). Pain-
ful defecation and the presence of abdominal or rectal
mass were not significantly different between the periods
on NF and SF.
Safety
Throughout the study there were no serious adverse effects
in either group. Both formulas were well tolerated. Weight
gain was similar in both feeding groups. In period 1 NF
fed-infants gained 29.7 grams/day whereas weight gain in
infants fed SF was 32.2 grams/day (difference of means, -
2.6; 95% CI, -11.7 – 6.6; p = 0.57). In the subgroup that
completed the cross-over phase of the study, growth was
not significantly different between the periods on NF and
on SF; 28.2 grams/day versus 33.5 grams/day respectively
(difference of means, -5.4; 95% CI, -13.0 – 2.3; p = 0.16).
Discussion
To our knowledge this is the first double-blind cross-over
study evaluating the effect of Nutrilon Omneo (NF) on
stool characteristics in infants with constipation. Our data
show that constipated infants with hard stools fed NF,
containing a high proportion of sn-2 palmitic acid and a
mixture of prebiotic oligosaccharides, improved more
often to softer stools compared to whey-based SF-fed
infants. Defecation frequency increased significantly com-
pared to baseline in both groups, but was not different
between the NF-fed and SF-fed infants. The formula was
well tolerated and growth rates were similar on both for-
mulas.
Previous studies in healthy infants revealed a wide varia-
bility in defecation frequency depending on age and the
type of feeding [21,24,25]. Fontana et al. showed a decline
in defecation frequency from an average of 3 stools per
day in the first month of life to 1.4 per day at 3 years of age
[24]. Furthermore, breast-fed infants have a defecation
frequency twice as high as formula-fed infants in the first
12 weeks of life [21]. In this study in infants with consti-
pation, the mean defecation frequency at enrollment was
Table 3: Clinical efficacy of SF versus NF after period 1
SF (n = 15) NF (n = 20) Difference of means (95% CI)* RR (95% CI)** P-value
Defecation frequency (mean ± SD) 4.9 ± 2.5 5.6 ± 2.8 0.7 (-0.8–2.3) 0.36
Improvement of hard to soft stools (n) 50% (5/10) 90% (9/10) 1.8 (0.9–3.5) 0.14
No painful defecation (n) 33% (5/15) 35% (7/20) 1.0 (0.4–2.7) 0.92
No abdominal or rectal mass (n) 93% (14/15) 90% (18/20) 1.0 (0.8–1.2) 0.73
* ANCOVA; ** χ2 tests
Table 2: Baseline characteristics of infants with functional constipation by randomized group
Characteristics SF (n = 18) NF (n = 20) P- value
Number of boys (%) 11 (61) 8(40) 0.19
Age at intake (in months)
median 1.8 1.7 0.80
min-max 1.1–5.0 0.7–3.7
Age of onset (in weeks)
median 2.0 2.0 0.45
min-max 0–20 0–6
Defecation frequency
N/week (mean ± SD) 3.6 ± 1.8 3.5 ± 2.6 0.64
< 3 times/week 39% 50% 0.49
Hard stool consistency 72% 50% 0.16
Painful defecation 89% 75% 0.27
Abdominal scybalus 44% 20% 0.13
Rectal scybalus 29% 21% 0.51
Meconium passage < 48 hours 100% 90% 0.32
Positive family history 61% 58% 0.84Nutrition Journal 2007, 6:8 http://www.nutritionj.com/content/6/1/8
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3.5 times per week. A total of 45% of all infants presented
with a defecation frequency of < 3 times/week. Two recent
follow-up studies in constipated infants found different
defecation frequencies at enrollment of 6.5 times per
week and 2 times per week, respectively [26,27]. This dis-
parity is most likely explained by the difference in patient
populations. The study by Loening-Baucke et al. and our
study were conducted in infants referred to general pedi-
atric out-patient clinics. In the study by Van den Berg et al.
only infants with severe functional constipation that
required referral to a specialized clinic to rule out Hirschs-
prung's disease were included. The difference in age distri-
bution between the studies may also have contributed to
the difference in outcome, since we included younger
infants up to 5 months of age, but the other two studies
included children up to a maximum of 2 years of age
[26,27].
In comparison to these recent follow-up studies in consti-
pated infants, we found a higher percentage of infants
with painful defecation (82%). Hard stool consistency in
more than half of the infants just partially explains this
finding, since the presence of painful defecation did not
improve in accordance with a softer stool consistency.
Loening-Baucke et al. reported hard stool consistency in
93% of all constipated children and painful defecation in
only 41%. Van de Berg et al. did not report on stool con-
sistency, but painful defecation was present in 49% of the
infants. Differences may be explained by the fact that
painful defecation at this young age is a very subjective
measurement and difficult to objectify by a parent on a
daily basis. The fact that this study was a multi-centre trial
may also have lead to an inter-observer difference in the
registration of changes in painful defecation.
In our analysis infants receiving NF showed more
improvement of hard stools to soft stools than those fed
SF, although significance was only reached in infants
completing the cross-over study. This result is in line with
the findings of two previous studies demonstrating softer
stools in healthy term infants fed high sn-2 palmitate for-
mula [9,15]. This effect is attributed to a reduced fecal
excretion of calcium-fatty acid soaps [5,28]. Another
explanation for the difference in stool consistency is most
likely the addition of a prebiotic mixture of GOS/lcFOS in
the Nutrilon Omneo formula. Earlier studies in healthy
infants have shown that supplementation of an infant for-
mula with this mixture resulted in an increased number of
fecal Bifidobacteria and softer stool consistency [23,29,30].
Moro et al. found that this effect was dose-dependent and
softer stools were comparable to stools of breast-fed
infants at a level of 0.8 g/100 ml of GOS/FOS mixture
[30]. Similar to our results, Schmelzle et al. showed softer
stools, but no statistical difference in defecation frequency
in healthy term infants fed NF [23]. This positive effect on
stool consistency is of clinical importance in our patient
population, as a majority of infants (61%) presented with
hard stool consistency as main symptom of their consti-
pation.
Additionally, previous studies have shown that formulas
containing hydrolyzed protein can produce softer stools
[31]. Therefore, the presence of hydrolyzed whey protein
may also have contributed to the stool softening effect of
NF. In this respect, the addition of some hydrolyzed pro-
tein (about 25% of total protein) to SF may explain the
observed increase of defecation frequency on both formu-
las. However, the observed increase in defecation fre-
quency was stronger in infants fed NF than those fed SF,
but no significant difference was found.
A limitation of this study is that more than one third of
the constipated infants enrolled did not complete the
study protocol. Due to this high drop-out rate, no cross-
over data was available from these children resulting in
loss of power in our analysis. Therefore our findings on
defecation frequency and stool consistency need to be
confirmed in a larger clinical trial in order to gain more
insight into the effects of the composition of this NF.
This drop-out rate is of further concern because it may
potentially introduce a bias. However, besides a signifi-
cantly lower age at enrollment in the drop-out group,
baseline characteristics showed no difference between the
infants who dropped out and the remaining infants. There
was a relationship between the drop-out rate and the feed-
ing type, since the most important reasons for drop-out
were: 1) a significant improvement after the first treat-
ment period on NF, or 2) the recurrence of symptoms of
constipation after the switch to SF in the second period.
Understandably, parents refused to continue the study
when their infant had improved or when symptoms of
constipation recurred. In general, parents of sick children
have emotional and ethical problems to accept the risk of
recurrence of the initial symptoms. The latter is probably
the reason for the lack of scientific data evaluating the
effect of infant formulas or oral laxatives in infants with
constipation.
In conclusion, this study demonstrates that the use of an
infant formula with a high proportion of sn-2 palmitate, a
mixture of prebiotic galacto-oligosaccharides and fructo-
oligosaccharides and partially hydrolyzed whey protein
may lead to softer stools in constipated infants. Thus, con-
stipated infants who present with hard stools may benefit
from a change form SF to this NF as a first treatment step,
but larger randomized clinical trials on the efficacy of this
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